Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Treatment options in patients with systemic sclerosis-associated interstitial lung disease

    Treatment options in patients with systemic sclerosis-associated interstitial lung disease

    FromThe Lancet Respiratory Medicine in conversation with

    Start listeningView podcast show

    Treatment options in patients with systemic sclerosis-associated interstitial lung disease

    FromThe Lancet Respiratory Medicine in conversation with

    ratings:
    Length:
    16 minutes
    Released:
    Jan 5, 2021
    Format:
    Podcast episode

    Description

    Toby Maher discusses the results of the SENSCIS trial, looking at the safety and efficacy of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD) treated with mycophenolate.Read the full article:https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30458-6/fulltext
    Released:
    Jan 5, 2021
    Format:
    Podcast episode

    Titles in the series (100)

    Editors speak to the journal’s authors to explore their research and its impact on people’s health, health care, and health policy in this regular podcast.